期刊文献+

2型糖尿病患者骨密度改变的多因素分析 被引量:2

Muiti factor analysis changes bone mineral density in patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的 探讨 2型糖尿病老年患者骨密度改变 ,以了解 2型糖尿病患者骨质疏松与其相关影响因素的关系。方法 采用双能X线骨密度仪 ,测定 2型糖尿病老年男性患者 30例、女性患者75例 ,按女性骨密度是否出现骨质疏松分为骨质疏松组与无骨质疏松组 ,并根据年龄、病程、绝经年限、体重指数、性激素、钙、碱性磷酸酶进行比较及相关性分析。结果 女性骨质疏松组年龄较大、绝经年限延长、孕酮水平低 ;骨密度无论男女与其病程呈负相关 ,与体重指数呈正相关关系 ;男女腰椎体以L1骨密度最低。结论  2型糖尿病患者绝经后时间越长则越易发生骨质疏松 ,体重指数和性激素减低加重骨密度丢失。 Objective To investigate the relationship between changes in bone mineral density and contributory factors in old patients with type 2 diabetes mellitus. Methods Lumber vertebral bone mineral densities in 30 old male and 75 old female patients with type 2 diabetes were measured by dual energy X-ray absorptiometry, and divided into osteoporotic (OP)group and non-osteoporotic (NOP) group in the 75 female diabetic patients according to existence or not of osteoporosis, and various factors such as age, course of diease, duration of menopause, body mass index(BMI), sexual hormone, calcium, and alkaline phosphatase werw compared between OP group and NOP group and anakad. Results The parameters of age, duration of menopause, and progesterone were factors influenciag of occurrence steoporosis, and the bone mineral densities in old male and female patients with type 2 diabetes were negatively correlated with course of disease and positively correlated with body mass index. Bone mineral density values of the first lumbar vertebra (L 1) were lowest in old men and women. Conclusion The incidence of osteoporosis increases with increasing duration of menopause. Declinein body mass index or sexual hormone will aggravate bone mineral loss.
作者 童书云
出处 《中国骨质疏松杂志》 CAS CSCD 2004年第3期314-315,346,共3页 Chinese Journal of Osteoporosis
关键词 骨密度 2型糖尿病 患者 骨质疏松 体重指数 改变 绝经年限 多因素分析 性激素 病程 Type 2 diabetes mellitus Bone mineral density Dual energy X-ray absorptiometry Sexual hormone
  • 相关文献

参考文献7

  • 1Tuominen TJ, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care, 1999,22:1196-1200.
  • 2Weber B, Baccaria L, de Angelis M, et al. Bone mass in young patients with type 1 diabetes. Bone Miner, 1990, 8:23-30.
  • 3Takagi M, Kasayama S, Yamamoto T, et al. Advanced glycosylation endproducts stimulate interleukin-6 production by human bone-derived cells.J Bone Miner Res, 1997,12:439-446.
  • 4Onoe Y. Miyaura C, Ito M, et al. Comparative effects of estrogen and ralosifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res, 2000, 15:541-549.
  • 5Nawata H, Tanaka S, Tanaka S, et al. Aromatase in bone cell: association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol, 1995,53:165-174.
  • 6Hofbauer LC, Khosla S. Androgen effects on bone metabolism: recent progresss and controversies. Eur J Endocrinol, 1999,140:217-286.
  • 7Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis.N Engl J Med, 1995,10:1294-1297.

同被引文献13

  • 1李万根,宫雅南,林伟,武兆忠,区品中.2型糖尿病患者与正常人骨密度的比较[J].中华糖尿病杂志(1006-6187),2005,13(1):52-54. 被引量:32
  • 2Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal over-weight women. Eur J Epidemiol,2004,19 : 1105-1112.
  • 3Nakashima A, Nashima R, Ito T, et al. HMG-COA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus. Diabet Med, 2004,21:1020-1024.
  • 4Suzuki K, Sugimoto C, Takizawa M, et al. Correlations between bone mineral density and circulation bone metabolic markers in diabetic patients. Diabetes Res Clin Bact,2000 ,48 :185-191.
  • 5Van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin- dependent diabetes mellitus. Ann Intern Med, 1995,123:731.
  • 6OZ SG, Guven GS, Kilicarslan A, et al. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc. 2006,98 : 1598-609.
  • 7Leidig-Bruckner G ,Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes. 2001,109( Suppl 2) :S493-514.
  • 8Komatsu Y, Majima T. Negative correlation between BMD and Hba1c in patients with type 2 diabetes. Clin Calcium, 2006,16:67-71.
  • 9Thraikill KM, Lumpkin CK Jr, Bunn RC, et al. Is insulin an anabolie agent in bone? Dissecting the diabetic bone for clues. Am J Physio Endocinol Metab,2005,289 : E735-45.
  • 10Watanabe S, Takeuehi Y, Fukumoto S, et al. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab,2003,21:166-171.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部